Johnson & Johnson (JNJ)
Summary
JNJ Chart
4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise
A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street.
Johnson & Johnson Stock Could Be Waking Up
Johnson & Johnson's stock appears undervalued, as sluggish revenue growth and margin contraction are offset by raised full-year guidance and a rebounding outlook. Both Innovative Medicine and MedTech segments show promising pipeline developments, with MedTech's growth and robotics ambitions offering future upside. Despite a dip in free cash flow, J&J's dividend remains attractive, with a solid 3.18% yield and a 62-year growth streak, supporting shareholder returns.
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Johnson & Johnson Dividends
| JNJ 23 May 2022 | Other | $1.13 Per Share |
| JNJ 18 Feb 2022 | Other | $1.06 Per Share |
| JNJ 22 Nov 2021 | Other | $1.06 Per Share |
| JNJ 23 Aug 2021 | Other | $1.06 Per Share |
| JNJ 24 May 2021 | Other | $1.06 Per Share |
Johnson & Johnson Earnings
| 31 Dec 2016 Date | | - Cons. EPS | 1.38 EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 1.53 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | 1.43 EPS |
| 31 Mar 2016 Date | | - Cons. EPS | 1.54 EPS |
| 31 Dec 2015 Date | | - Cons. EPS | 1.15 EPS |
| JNJ 23 May 2022 | Other | $1.13 Per Share |
| JNJ 18 Feb 2022 | Other | $1.06 Per Share |
| JNJ 22 Nov 2021 | Other | $1.06 Per Share |
| JNJ 23 Aug 2021 | Other | $1.06 Per Share |
| JNJ 24 May 2021 | Other | $1.06 Per Share |
| 31 Dec 2016 Date | | - Cons. EPS | 1.38 EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 1.53 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | 1.43 EPS |
| 31 Mar 2016 Date | | - Cons. EPS | 1.54 EPS |
| 31 Dec 2015 Date | | - Cons. EPS | 1.15 EPS |
Johnson & Johnson (JNJ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Johnson & Johnson ever had a stock split?
Johnson & Johnson Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Joaquin Duato CEO | XSGO Exchange | US4781601046 ISIN |
| US Country | 138,100 Employees | 18 Feb 2025 Last Dividend | 13 Jun 2001 Last Split | - IPO Date |
Overview
Johnson & Johnson, a renowned entity in the healthcare sector, operates globally with a broad focus on research, development, manufacturing, and sales of healthcare products. The company is structured in multiple segments, primarily Innovative Medicine and MedTech, catering to a vast array of therapeutic areas and medical needs. Founded in 1886, the company is headquartered in New Brunswick, New Jersey, illustrating a longstanding presence and commitment to healthcare innovation and advancement. Through its extensive product line and diversified service offerings, Johnson & Johnson reaches a wide audience, including retailers, wholesalers, distributors, hospitals, and healthcare professionals, providing prescription and non-prescription products alike.
Products and Services
The company's portfolio is divided into two main segments, each encompassing a variety of products and services designed to meet the complex demands of modern healthcare:
- Innovative Medicine:
This segment includes a range of products for different therapeutic areas. These encompass immunology (covering diseases like rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis), infectious diseases (including HIV/AIDS treatment), neuroscience (targeting mood disorders, neurodegenerative disorders, schizophrenia), oncology (focused on cancers such as prostate, lung, bladder, and hematologic malignancies), cardiovascular and metabolism (addressing conditions like thrombosis, diabetes, and macular degeneration), and pulmonary hypertension, specifically pulmonary arterial hypertension.
- MedTech:
This segment offers products and technologies across a range of medical fields. Interventional Solutions include electrophysiology products for heart rhythm disorders and technologies for severe coronary artery disease treatment. The neurovascular care line focuses on treating hemorrhagic and ischemic strokes. Orthopaedics products support treatments for hips, knees, trauma, spine, and sports injuries. The surgery portfolio covers advanced and general surgery technologies and solutions for breast aesthetics and ear, nose, and throat procedures. Additionally, MedTech offers visual health products like ACUVUE Brand contact lenses and TECNIS intraocular lenses for cataract surgery.
Contact Information
